+关注
Mistycher
暂无个人介绍
IP属地:未知
7
关注
1
粉丝
0
主题
0
勋章
主贴
热门
Mistycher
2021-10-17
Wow
Wall St ends higher as Goldman rounds out parade of strong bank results
Mistycher
2021-10-17
Ok
抱歉,原内容已删除
Mistycher
2021-11-29
I bought! 🤣
Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4097016493991950,"uuid":"4097016493991950","gmtCreate":1633924507519,"gmtModify":1634009324648,"name":"Mistycher","pinyin":"mistycher","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":7,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":600488852,"gmtCreate":1638187806727,"gmtModify":1638187944855,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I bought! 🤣","listText":"I bought! 🤣","text":"I bought! 🤣","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600488852","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers <b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and <b>Novavax</b>(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its <b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8 <a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827826962,"gmtCreate":1634445556598,"gmtModify":1634445556667,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827826962","repostId":"2175146556","repostType":4,"repost":{"id":"2175146556","pubTimestamp":1634328035,"share":"https://www.laohu8.com/m/news/2175146556?lang=&edition=full","pubTime":"2021-10-16 04:00","market":"us","language":"en","title":"Wall St ends higher as Goldman rounds out parade of strong bank results","url":"https://stock-news.laohu8.com/highlight/detail?id=2175146556","media":"Reuters","summary":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news","content":"<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)</p>\n<ul>\n <li>Retail sales up 0.7% in September despite shortages</li>\n <li>Goldman Sachs rises on strong third-quarter earnings (New throughout, updates prices, market activity and comments to close)</li>\n</ul>\n<p>NEW YORK, Oct 15 (Reuters) - U.S. stocks ended higher on Friday after Goldman Sachs became the latest big bank to report strong quarterly earnings, and Wall Street's three major indexes posted gains for the week.</p>\n<p>Goldman Sachs Group shares jumped, giving the Dow its biggest boost, as a record wave of dealmaking activity drove a surge in the bank's quarterly profit.</p>\n<p>Other big lenders also rose and were among the biggest positive for the S&P 500. The index's bank index ended sharply higher.</p>\n<p>Results from the big financial institutions this week have provided a strong start to third-quarter U.S. earnings, though investors will still watch in coming weeks for signs of impacts from supply chain disruptions and higher costs, especially for energy.</p>\n<p>Forecasts now call for S&P 500 earnings to show a 32% rise in the third quarter from a year ago. The latest forecast, based on results from 41 of the S&P 500 companies and estimates for the rest, is up from 29.4% at the start of October, according to IBES data from Refinitiv.</p>\n<p>\"We're starting to get into an earnings-driven rally here that I hope lasts. We'll really see the results in the next couple of weeks as a great bulk of companies in all sectors report,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.</p>\n<p>Alcoa Corp shares surged after the aluminum producer reported stronger-than-expected results, announced a $500 million buyback program and initiated a quarterly cash dividend.</p>\n<p>According to preliminary data, the S&P 500 gained 33.35 points, or 0.75%, to end at 4,471.61 points, while the Nasdaq Composite gained 73.55 points, or 0.50%, to 14,896.98. The Dow Jones Industrial Average rose 384.83 points, or 1.10%, to 35,297.39.</p>\n<p>The U.S. Commerce Department reported a surprise rise in retail sales in September, although investors still worried that supply constraints could disrupt the holiday shopping season. A preliminary reading for consumer sentiment in October came in slightly below expectations.</p>\n<p>Some airline and other travel-related company shares edged higher, with the White House announcing it will lift travel restrictions for fully-vaccinated foreign nationals effective Nov. 8.</p>\n<p>Moderna Inc shares were lower. A Wall Street Journal report, citing people familiar with the matter, said the U.S. Food and Drug Administration is delaying its decision on authorizing Moderna's COVID-19 vaccine for adolescents to check if the shot could increase the risk of heart inflammation.</p>\n<p>On Thursday, an FDA panel voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and high-risk people.</p>\n<p>Shares of cryptocurrency and blockchain-related firms including Riot Blockchain gained as bitcoin hit $60,000 for the first time since April. (Additional reporting by Devik Jain in Bengaluru and Federica Urso in Gdansk; Editing by Anil D'Silva, Arun Koyyur and Nick Zieminski)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St ends higher as Goldman rounds out parade of strong bank results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St ends higher as Goldman rounds out parade of strong bank results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-16 04:00 GMT+8 <a href=https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n\nRetail sales up 0.7% in September despite shortages\nGoldman Sachs rises on strong third-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COMP":"Compass, Inc.","GSBD":"高盛BDC基金","GS":"高盛"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2175146556","content_text":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n\nRetail sales up 0.7% in September despite shortages\nGoldman Sachs rises on strong third-quarter earnings (New throughout, updates prices, market activity and comments to close)\n\nNEW YORK, Oct 15 (Reuters) - U.S. stocks ended higher on Friday after Goldman Sachs became the latest big bank to report strong quarterly earnings, and Wall Street's three major indexes posted gains for the week.\nGoldman Sachs Group shares jumped, giving the Dow its biggest boost, as a record wave of dealmaking activity drove a surge in the bank's quarterly profit.\nOther big lenders also rose and were among the biggest positive for the S&P 500. The index's bank index ended sharply higher.\nResults from the big financial institutions this week have provided a strong start to third-quarter U.S. earnings, though investors will still watch in coming weeks for signs of impacts from supply chain disruptions and higher costs, especially for energy.\nForecasts now call for S&P 500 earnings to show a 32% rise in the third quarter from a year ago. The latest forecast, based on results from 41 of the S&P 500 companies and estimates for the rest, is up from 29.4% at the start of October, according to IBES data from Refinitiv.\n\"We're starting to get into an earnings-driven rally here that I hope lasts. We'll really see the results in the next couple of weeks as a great bulk of companies in all sectors report,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.\nAlcoa Corp shares surged after the aluminum producer reported stronger-than-expected results, announced a $500 million buyback program and initiated a quarterly cash dividend.\nAccording to preliminary data, the S&P 500 gained 33.35 points, or 0.75%, to end at 4,471.61 points, while the Nasdaq Composite gained 73.55 points, or 0.50%, to 14,896.98. The Dow Jones Industrial Average rose 384.83 points, or 1.10%, to 35,297.39.\nThe U.S. Commerce Department reported a surprise rise in retail sales in September, although investors still worried that supply constraints could disrupt the holiday shopping season. A preliminary reading for consumer sentiment in October came in slightly below expectations.\nSome airline and other travel-related company shares edged higher, with the White House announcing it will lift travel restrictions for fully-vaccinated foreign nationals effective Nov. 8.\nModerna Inc shares were lower. A Wall Street Journal report, citing people familiar with the matter, said the U.S. Food and Drug Administration is delaying its decision on authorizing Moderna's COVID-19 vaccine for adolescents to check if the shot could increase the risk of heart inflammation.\nOn Thursday, an FDA panel voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and high-risk people.\nShares of cryptocurrency and blockchain-related firms including Riot Blockchain gained as bitcoin hit $60,000 for the first time since April. (Additional reporting by Devik Jain in Bengaluru and Federica Urso in Gdansk; Editing by Anil D'Silva, Arun Koyyur and Nick Zieminski)","news_type":1},"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827828773,"gmtCreate":1634445521725,"gmtModify":1634445521794,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827828773","repostId":"1159233677","repostType":4,"repost":{"id":"1159233677","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1634309637,"share":"https://www.laohu8.com/m/news/1159233677?lang=&edition=full","pubTime":"2021-10-15 22:53","market":"fut","language":"en","title":"U.S. Treasury warns crypto industry on preventing sanctions violations","url":"https://stock-news.laohu8.com/highlight/detail?id=1159233677","media":"Reuters","summary":"WASHINGTON, Oct 15 (Reuters) - In its broad effort to reduce the use of crypto currencies in the pay","content":"<p>WASHINGTON, Oct 15 (Reuters) - In its broad effort to reduce the use of crypto currencies in the payment of ransomware demands, the U.S. Treasury said on Friday that the crypto community is responsible for making sure they do not directly or indirectly help facilitate deals that are prohibited by U.S. sanctions.</p>\n<p>\"The virtual currency industry, including technology companies, exchangers, administrators, miners, wallet providers, and users, plays an increasingly critical role in preventing sanctioned persons from exploiting virtual currencies to evade sanctions and undermine U.S. foreign policy and national security interests,\" Treasury said in new guidance.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Treasury warns crypto industry on preventing sanctions violations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Treasury warns crypto industry on preventing sanctions violations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-15 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, Oct 15 (Reuters) - In its broad effort to reduce the use of crypto currencies in the payment of ransomware demands, the U.S. Treasury said on Friday that the crypto community is responsible for making sure they do not directly or indirectly help facilitate deals that are prohibited by U.S. sanctions.</p>\n<p>\"The virtual currency industry, including technology companies, exchangers, administrators, miners, wallet providers, and users, plays an increasingly critical role in preventing sanctioned persons from exploiting virtual currencies to evade sanctions and undermine U.S. foreign policy and national security interests,\" Treasury said in new guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","GBTC":"Grayscale Bitcoin Trust"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159233677","content_text":"WASHINGTON, Oct 15 (Reuters) - In its broad effort to reduce the use of crypto currencies in the payment of ransomware demands, the U.S. Treasury said on Friday that the crypto community is responsible for making sure they do not directly or indirectly help facilitate deals that are prohibited by U.S. sanctions.\n\"The virtual currency industry, including technology companies, exchangers, administrators, miners, wallet providers, and users, plays an increasingly critical role in preventing sanctioned persons from exploiting virtual currencies to evade sanctions and undermine U.S. foreign policy and national security interests,\" Treasury said in new guidance.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":827826962,"gmtCreate":1634445556598,"gmtModify":1634445556667,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827826962","repostId":"2175146556","repostType":4,"repost":{"id":"2175146556","pubTimestamp":1634328035,"share":"https://www.laohu8.com/m/news/2175146556?lang=&edition=full","pubTime":"2021-10-16 04:00","market":"us","language":"en","title":"Wall St ends higher as Goldman rounds out parade of strong bank results","url":"https://stock-news.laohu8.com/highlight/detail?id=2175146556","media":"Reuters","summary":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news","content":"<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)</p>\n<ul>\n <li>Retail sales up 0.7% in September despite shortages</li>\n <li>Goldman Sachs rises on strong third-quarter earnings (New throughout, updates prices, market activity and comments to close)</li>\n</ul>\n<p>NEW YORK, Oct 15 (Reuters) - U.S. stocks ended higher on Friday after Goldman Sachs became the latest big bank to report strong quarterly earnings, and Wall Street's three major indexes posted gains for the week.</p>\n<p>Goldman Sachs Group shares jumped, giving the Dow its biggest boost, as a record wave of dealmaking activity drove a surge in the bank's quarterly profit.</p>\n<p>Other big lenders also rose and were among the biggest positive for the S&P 500. The index's bank index ended sharply higher.</p>\n<p>Results from the big financial institutions this week have provided a strong start to third-quarter U.S. earnings, though investors will still watch in coming weeks for signs of impacts from supply chain disruptions and higher costs, especially for energy.</p>\n<p>Forecasts now call for S&P 500 earnings to show a 32% rise in the third quarter from a year ago. The latest forecast, based on results from 41 of the S&P 500 companies and estimates for the rest, is up from 29.4% at the start of October, according to IBES data from Refinitiv.</p>\n<p>\"We're starting to get into an earnings-driven rally here that I hope lasts. We'll really see the results in the next couple of weeks as a great bulk of companies in all sectors report,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.</p>\n<p>Alcoa Corp shares surged after the aluminum producer reported stronger-than-expected results, announced a $500 million buyback program and initiated a quarterly cash dividend.</p>\n<p>According to preliminary data, the S&P 500 gained 33.35 points, or 0.75%, to end at 4,471.61 points, while the Nasdaq Composite gained 73.55 points, or 0.50%, to 14,896.98. The Dow Jones Industrial Average rose 384.83 points, or 1.10%, to 35,297.39.</p>\n<p>The U.S. Commerce Department reported a surprise rise in retail sales in September, although investors still worried that supply constraints could disrupt the holiday shopping season. A preliminary reading for consumer sentiment in October came in slightly below expectations.</p>\n<p>Some airline and other travel-related company shares edged higher, with the White House announcing it will lift travel restrictions for fully-vaccinated foreign nationals effective Nov. 8.</p>\n<p>Moderna Inc shares were lower. A Wall Street Journal report, citing people familiar with the matter, said the U.S. Food and Drug Administration is delaying its decision on authorizing Moderna's COVID-19 vaccine for adolescents to check if the shot could increase the risk of heart inflammation.</p>\n<p>On Thursday, an FDA panel voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and high-risk people.</p>\n<p>Shares of cryptocurrency and blockchain-related firms including Riot Blockchain gained as bitcoin hit $60,000 for the first time since April. (Additional reporting by Devik Jain in Bengaluru and Federica Urso in Gdansk; Editing by Anil D'Silva, Arun Koyyur and Nick Zieminski)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St ends higher as Goldman rounds out parade of strong bank results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St ends higher as Goldman rounds out parade of strong bank results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-16 04:00 GMT+8 <a href=https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n\nRetail sales up 0.7% in September despite shortages\nGoldman Sachs rises on strong third-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COMP":"Compass, Inc.","GSBD":"高盛BDC基金","GS":"高盛"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-st-ends-200035041.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2175146556","content_text":"(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)\n\nRetail sales up 0.7% in September despite shortages\nGoldman Sachs rises on strong third-quarter earnings (New throughout, updates prices, market activity and comments to close)\n\nNEW YORK, Oct 15 (Reuters) - U.S. stocks ended higher on Friday after Goldman Sachs became the latest big bank to report strong quarterly earnings, and Wall Street's three major indexes posted gains for the week.\nGoldman Sachs Group shares jumped, giving the Dow its biggest boost, as a record wave of dealmaking activity drove a surge in the bank's quarterly profit.\nOther big lenders also rose and were among the biggest positive for the S&P 500. The index's bank index ended sharply higher.\nResults from the big financial institutions this week have provided a strong start to third-quarter U.S. earnings, though investors will still watch in coming weeks for signs of impacts from supply chain disruptions and higher costs, especially for energy.\nForecasts now call for S&P 500 earnings to show a 32% rise in the third quarter from a year ago. The latest forecast, based on results from 41 of the S&P 500 companies and estimates for the rest, is up from 29.4% at the start of October, according to IBES data from Refinitiv.\n\"We're starting to get into an earnings-driven rally here that I hope lasts. We'll really see the results in the next couple of weeks as a great bulk of companies in all sectors report,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia.\nAlcoa Corp shares surged after the aluminum producer reported stronger-than-expected results, announced a $500 million buyback program and initiated a quarterly cash dividend.\nAccording to preliminary data, the S&P 500 gained 33.35 points, or 0.75%, to end at 4,471.61 points, while the Nasdaq Composite gained 73.55 points, or 0.50%, to 14,896.98. The Dow Jones Industrial Average rose 384.83 points, or 1.10%, to 35,297.39.\nThe U.S. Commerce Department reported a surprise rise in retail sales in September, although investors still worried that supply constraints could disrupt the holiday shopping season. A preliminary reading for consumer sentiment in October came in slightly below expectations.\nSome airline and other travel-related company shares edged higher, with the White House announcing it will lift travel restrictions for fully-vaccinated foreign nationals effective Nov. 8.\nModerna Inc shares were lower. A Wall Street Journal report, citing people familiar with the matter, said the U.S. Food and Drug Administration is delaying its decision on authorizing Moderna's COVID-19 vaccine for adolescents to check if the shot could increase the risk of heart inflammation.\nOn Thursday, an FDA panel voted to recommend booster shots of its COVID-19 vaccine for Americans aged 65 and older and high-risk people.\nShares of cryptocurrency and blockchain-related firms including Riot Blockchain gained as bitcoin hit $60,000 for the first time since April. (Additional reporting by Devik Jain in Bengaluru and Federica Urso in Gdansk; Editing by Anil D'Silva, Arun Koyyur and Nick Zieminski)","news_type":1},"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827828773,"gmtCreate":1634445521725,"gmtModify":1634445521794,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827828773","repostId":"1159233677","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600488852,"gmtCreate":1638187806727,"gmtModify":1638187944855,"author":{"id":"4097016493991950","authorId":"4097016493991950","authorIdStr":"4097016493991950","name":"Mistycher","avatar":"https://static.tigerbbs.com/cf0d9a345c1250a7e127338f228b9e36","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I bought! 🤣","listText":"I bought! 🤣","text":"I bought! 🤣","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600488852","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers <b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and <b>Novavax</b>(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its <b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8 <a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}